Sign In
Buy BDX
$145.61
+1.18 (+0.82%)
At Close: Jun 03, 2026
BD Chases End-To-End Supply Chain Visibility
09:44am, Friday, 02'nd Sep 2022
BD had a supply chain risk management solution. It provided good visibility to their Tier 1 suppliers.
BD to Present at the Wells Fargo 2022 Healthcare Conference
04:15pm, Wednesday, 24'th Aug 2022
FRANKLIN LAKES, N.J. , Aug. 24, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Far
BD's (BDX) Latest Collaboration to Boost Patient Outcome
01:28pm, Thursday, 18'th Aug 2022 Zacks Investment Research
BD's (BDX) tie-up with Accelerate Diagnostics is expected to strengthen the fight to combat the global threat of antimicrobial resistance, thereby boosting patient care.
3 Top Dividend Kings to Buy for the Long Haul
01:10pm, Thursday, 18'th Aug 2022 The Motley Fool
You'll need to hold these stocks for many years to get the full benefit of their consistent dividend growth.
3 Top Dividend Kings to Buy for the Long Haul
09:10am, Thursday, 18'th Aug 2022
You'll need to hold these stocks for many years to get the full benefit of their consistent dividend growth.
5 Analysts Have This to Say About Becton, Dickinson
03:09pm, Tuesday, 16'th Aug 2022 Benzinga
Within the last quarter, Becton, Dickinson (NYSE:BDX) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
0
0
1
Last
Salesforce To $273? Plus This Analyst Boosts Price Target On Snowflake
02:19pm, Tuesday, 16'th Aug 2022 Benzinga
Morgan Stanley cut the price target on Salesforce, Inc. (NYSE: CRM) from $291 to $273. Salesforce shares fell 1.7% to trade at $187.83 on Tuesday.
Barclays boosted the price target for Snowflake Inc
BD (BDX) Ties Up With LabCorp to Boost Patient Outcome
02:00pm, Monday, 15'th Aug 2022 Zacks Investment Research
BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.
Zimmer Biomet (ZBH) Sees Business Recovery, Global Growth
01:29pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.
7 Blue-Chip Stocks That Will Survive 2022
10:23am, Tuesday, 09'th Aug 2022
Buying high-quality blue-chip stocks in a bear market could be a solid path to generating lucrative long-term returns. Blue-chip stocks are typically large-cap businesses in the mature stage of their
Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark
01:09pm, Monday, 08'th Aug 2022 Zacks Investment Research
According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.
Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised
04:58pm, Friday, 05'th Aug 2022 Zacks Investment Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.
QuidelOrtho (QDEL) Q2 Earnings Miss, Provides FY22 View
04:57pm, Friday, 05'th Aug 2022 Zacks Investment Research
QuidelOrtho's (QDEL) robust performance across majority of its business units and geographies drives its second-quarter 2022 top line.
AMN Healthcare (AMN) Q2 Earnings, Revenues Beat Estimates
04:56pm, Friday, 05'th Aug 2022 Zacks Investment Research
AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.
Should You Really Care About This Company's Short-Term Success?
10:00am, Friday, 05'th Aug 2022 The Motley Fool
Abbott Laboratories' growth looks much less impressive after removing sales from COVID-19 diagnostics.
